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A striking common feature of most autoimmune diseases is their female predominance, 
with at least twice as common among women than men in relapsing–remitting multiple 
sclerosis (MS), the prevailing MS clinical form with onset at childbearing age. This fact, 
together with the protective effect on disease activity during pregnancy, when there are 
many biological changes including high levels of estrogens and progesterone, puts sex 
hormones under the spotlight. The role of natural killer (NK) and NKT cells in MS disease 
beginning and course is still to be elucidated. The uterine NK (uNK) cells are the most 
predominant immune population in early pregnancy, and the number and function of 
uNK cells infiltrating the endometrium are sex-hormones’ dependent. However, there 
is controversy on the role of estrogen or progesterone on circulating NK (CD56dim and 
CD56bright) and NKT cells’ subsets. Here, we show a significantly increased activation 
of CD3+CD56+CD8+ cells in pregnant MS women (MSP) compared with non-pregnant 
MS women (NPMS) (p < 0.001) and even with respect to healthy pregnant women (HP, 
p < 0.001), remaining increased even after delivery. The dynamics of expression of early 
activation marker CD69 on CD3+CD56+CD8+ cells showed a progressive statistically 
significant increase along the gestation trimesters (T) and at postpartum (PP) with respect 
to NPMS (1T: p = 0.018; 2T: p = 0.004; 3T: p < 0.001; PP: p = 0.001). In addition, early 
activation expression of CD69 on CD3+CD56+CD8+ cells was higher in MSP than HP 
in the first two trimesters of gestation (p = 0.004 and p = 0.015, respectively). NPMS 
showed significantly increased cytotoxic/regulatory NK ratio compared with healthy 
controls (p < 0.001). On the other hand, gender studies showed no differences between 
MS women and men in NK and CD3+CD56+CD8+ cells’ subsets. Our findings may add 
on the understanding of the regulatory axis in MS during pregnancy. Further studies on 
specific CD8+ NKT cells function and their role in pregnancy beneficial effects on MS are 
warranted to move forward more effective MS treatments.
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inTrODUcTiOn
Multiple sclerosis (MS) is a prototypic autoimmune inflamma-
tory disorder of the central nervous system (CNS), in which both 
adaptive and innate immune systems are assumed to participate 
in demyelination and neurodegeneration (1). Epidemiological 
data indicate that relapsing–remitting-MS is more prevalent in 
females than in males (3–2:1) (2), while men tend to develop a 
more severe and chronic form of the disease. Several factors have 
been proposed to contribute to gender bias in susceptibility to 
MS. The fact that MS is typically diagnosed in the fertile age turns 
to sex hormones, an important focus of study. For female patients 
with MS, pregnancy is one of the strongest known modulators 
of disease activity (3, 4), largely attributed to elevated levels of 
circulating sex hormones, such as estrogen or progesterone.
Natural killer (NK) cells are innate immune cells with a 
major role in eliminating virus-infected and tumor cells. Current 
evidences on the role of peripheral NK cells in exacerbating or 
dampening autoimmunity responses in MS are controversial (5). 
Peripheral NK cells’ activity has been reported to be reduced in 
the setting of MS (6–8), although its role in the pathophysiology 
of the disease is largely unknown. On the other hand, the uterine 
natural killer (uNK) cells are the most predominant immune 
population at the decidua in early pregnancy and disclose a 
regulatory phenotype, while its origin remains to be determined. 
However, effects of sex hormones on the immune system, and 
more specifically on peripheral NK and NKT cells, have not been 
clearly elucidated.
Two major functionally distinct subsets of NK cells have 
been described based on the relative expression of the markers 
CD16 and CD56 (9). Typically, the majority (approximately 
90%) of circulating NK cells have low expression of CD56 and 
high levels of CD16 and perforin, and display potent cytolytic 
activity (cytCD56dim). This subset can not only spontaneously 
lyse targeted tumor cells but also induce rapid inflammatory 
responses by releasing significant amounts of chemokines and 
proinflammatory cytokines when their activating receptors are 
engaged. By contrast, NK cells expressing high levels of CD56 and 
low CD16 are more abundant in secondary lymphoid tissues and 
tonsils (10, 11), and comprise nearly 70% of human decidual lym-
phocytes (9). Following monokine stimulation, CD56brightCD16− 
proliferate and produce immunoregulatory cytokines, including 
IFN-γ, TNF-α, and GM-CSF, and there is a general consensus in 
the literature that ascribe them a protective role in the neuron-
immunological context in MS (regCD56bright) (12).
NKT cells comprise a small subset of lymphocytes that pos-
sesses characteristics of both NK cells and conventional T cells, 
being able to release prototypical Th1 and Th2 cytokines after 
TCR ligation (13), and to induce perforin-, Fas-, and TNF-related 
cytotoxicity (14). Thus, these cells can have either protective or 
deleterious effects by promoting either inflammation or immune 
tolerance. Several studies have highlighted their regulatory role in 
autoimmune diseases, such as MS, type I diabetes mellitus, pri-
mary biliary cirrhosis, systemic lupus erythematosus, rheumatoid 
arthritis, psoriasis, and atherosclerosis, among others (15). NKT 
cells recognize lipid or glycolipid antigens presented by the MHC 
class I-related protein CD1d and exert their multiple functions, 
including antibacterial and antiviral immune responses, tumor-
related immunosurveillance or immunosuppression, and inhibi-
tion or promotion of the development of autoimmune diseases 
(16). Few studies have revealed alterations in the numbers (17, 
18) and functions of NKT cells in MS patients, despite MS is an 
organ-specific disease in which myelin lipids are a major target 
[reviewed in Ref. (19)]. The fact that specific NKT cells preva-
lence and function is restored in MS patients in remission after 
IFN-β treatment (12); that oral corticosteroids induce a Th2 bias 
in the cytokine profile of these cells (20); and that 1,25(OH)D3 
vitamin induce protection from EAE in mice dependent of NKT 
cell-derived IL-4 (21) suggests that NKT cells might exert immu-
noregulatory more than detrimental effects in MS. Depletion 
of iNKT in mice show a more severe EAE course (22). On the 
contrary, expanding iNKT protects from EAE by suppressing 
Th1 and Th17 responses (23, 24). Type II NKT cells exert also 
protective effects on EAE models (25). Further, activation of 
NKT cells with synthetic lipid antigens protects mice against the 
development of MS-like disease [reviewed in Ref. (26)]. Very 
little is known about the CD8+NKT role in MS. Interactions with 
other immunoregulatory cell types, such as regulatory T cells and 
immunosuppressive myeloid cells, might exert immunoregula-
tory effects in MS by producing Th2 cytokines [reviewed in Ref. 
(20)]. Further, CD8+NKT cells can function as antigen-specific 
suppressive cells to regulate the immune response through killing 
antigen-bearing DCs (27) and efficiently suppress the prolifera-
tion and expansion of activated T cells (28).
In this study, we sought to determine, first, the distribution 
of NK and NKT-like cells subsets according to sex and their 
involvement in the disease and pregnancy. Second and given the 
role of uNK cells in maternal tolerance during pregnancy, we 
explored the distribution of the NK and NKT-like cell subsets 
during normal and MS pregnancy, to ascertain whether they 
exert a role during pregnancy. To address this goal, we evalu-
ated the proportion and activation status (measured by CD69 
expression) of circulating NK subsets (regCD56bright and cytCD-
56dim) and CD3+CD56+CD8+ cells in both men and women from 
healthy subjects, MS patients, and pregnant women. Finally, we 
measured estrogens and progesterone levels in the luteal and fol-
licular phases of the menstrual cycle of healthy and MS women 
to assess the effects of the menstrual cycle and gender on NK 
activation.
PaTienTs anD MeThODs
subjects
A total of 124 subjects were studied. Among them, 70 MS patients, 
30 non-pregnant women (mean age 39.0 years, range 28–51), 10 
men (mean age 36.5 years, range 30–43), and 30 pregnant women 
(mean age 34 years, range 31–36) were consecutively recruited at 
the Unit of Multiple Sclerosis of the University General Hospital 
Gregorio Marañón of the Community of Madrid, Spain. All 
patients fulfilled definite MS diagnosis according to McDonald’s 
criteria (1). These patients had not received any immunomodula-
tory or immunosuppressive therapy in the previous 3 months and 
had non-active disease at the time of sample collection.
TaBle 1 | clinical and demographical characteristics of multiple 
sclerosis (Ms) patients and healthy controls (hc) included in the study: 
pregnant Ms women (MsP), non-pregnant Ms women (nPMs), Ms men, 
healthy pregnant women (hP), non-pregnant healthy control women 
(nPhc), and hc men.
MsP nPMs Ms men hP nPhc hc men
No. of 
patients
30 30 10 13 32 9
Age (years) 34 (31–36) 39 (28–51) 36 (30–43) 33 
(30–37)
28 
(21–39)
31 
(21–40)
EDSS 0 (1) (prior 
pregnancy)
1 (0–1.6) 1 (0.5–1.5) NA NA NA
Data are expressed as median (interquartile range).
EDSS, Expanded Disability Status Scale.
FigUre 1 | gating strategy for natural killer (nK) cells’ subsets and cD3+cD56+cD8+ cells. (a) Peripheral blood events were measured against forward and 
side scatter parameters, and total lymphocytes were selected. (B) Cells negative for CD3 were first selected and further displayed on a plot of CD16 vs. CD56 
expression. Cells negative for CD16 and positive for CD56 are CD3−CD56brightCD16− NK cells and CD3−CD56dimCD16+ NK cells. (c) CD3+CD56+ were analyzed 
gating on lymphocytes cells and selected from a plot of CD3 vs. CD56. CD3+CD56+CD8+ cells were selected afterward.
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A group of 54 age-matched healthy controls were recruited 
from volunteers at University General Hospital Gregorio 
Marañón during the same period: 32 women (mean age 28.1 years, 
range 21–39), 9 men (mean age 31.6  years, range 21–40), and 
13 pregnant women (mean age 33  years, range 30–37). All 32 
healthy women included in the study had regular menstrual 
cycles and were studied at days 1–3 and at day 14 (ovulation) of 
their menstrual cycle. None of HC and MS female had received 
treatment with glucocorticoids and contraceptive pills prior to 
the study inclusion. Clinical and demographic characteristics of 
individuals enrolled in the study are summarized in Table 1. The 
Ethics Committee of the institution approved the protocol, and all 
subjects provided their written informed consent.
nK and nKT cell subsets’ analysis
Lymphocyte subsets were analyzed using multiparametric flow-
cytometry analysis (FacsCANTO, BD Biosciences, San José, CA, 
USA). Cells were directly stained with the following monoclonal 
antibodies according to the manufacturer recommendations: 
CD69-FITC (Mouse Anti-Human CD69, Clone L78; BD 
Biosciences), CD16-PE (Mouse Anti-Human CD16, Clone 
B73.1; BD Biosciences), CD3-PerCP (Mouse Anti-Human CD3ϵ, 
Clone SK7; BD Biosciences), CD56-APC (Mouse Anti-Human 
CD56, Clone NCAM16.2; BD Biosciences), and CD8-APC-Cy7 
(Mouse Anti-Human CD8α, Clone SK1; BD Biosciences). IgG 
isotypic controls (BD Biosciences) were also tested to determine 
non-specific staining. Cells were incubated and protected from 
light at room temperature (RT) for 20 min. Afterward, cells were 
lysed (FACSTM-Lysing Solution; Becton Dickinson, San Jose, 
CA, USA), incubated again for 15  min in the dark, and then 
removed and washed with 2 mL phosphate-buffered saline. In the 
last step, a 6-color analysis was carried out using FACSCANTO 
flow cytometer (Becton Dickinson). Cell-Quest research (Becton 
Dickinson) and FlowJo (Tree Star, Ashland, OR, USA) software 
were used for the analysis. The gate was set for both FSC and SCC 
and included lymphocytes (Figure 1). A total of 20,000 events in 
the lymphocyte gate were acquired for each sample. After further 
gating on CD3− cells, the percentage of CD3−CD56brightCD16− 
and CD3−CD56dimCD16+ NK cell subsets was determined. 
CD3+CD56+CD8+ cells were analyzed in parallel on total lym-
phocytes. Although cell populations other than NKT cells might 
be included in the analysis, as minority subset of γδ-T cells, which 
FigUre 2 | Percentage of regcD56bright in non-pregnant healthy 
control women (nPhc) (n = 32) and hP (n = 13). The bar represents the 
median value, and individual dots indicate single donor values. Mann–
Whitney statistical test was used for calculation of the reported p-value. 
*p = 0.015 was considered to be statistically significant.
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This pattern was not evident in MS pregnancies. Instead, 
MSP showed a marked early activation of the three NK/NKT 
populations studied. The most remarkable finding was the sig-
nificantly increased CD3+CD56+CD8+ activation compared with 
non-pregnant MS women (NPMS) (p <  0.001) and even with 
HP (p < 0.001) (Figure 3A). This increase remained statistically 
significant and progressed during all the trimesters (T) of gesta-
tion and at postpartum (PP) with respect to NPMS (1T: p = 0.018; 
2T: p = 0.004; 3T: p < 0.001; PP: p = 0.001, respectively). Further, 
activation of CD3+CD56+CD8+ cells was even higher in MSP than 
HP in the first two trimesters of gestation (p = 0.004; p = 0.015, 
respectively). Specifically, during the second and third trimesters 
of gestation, there was an increased activation of regCD56bright NK 
in MS pregnancy compared to NPMS (2T: p = 0.063; 3T: p = 0.037) 
and even higher than HP during the second trimester (p = 0.033). 
Only at the third trimester, there was a slightly higher activation of 
the cytCD56dim NK subpopulation with respect to NPMS and HP 
(MSP vs. NPMS: p = 0.019; MSP vs. HP: p = 0.05) (Figure 3B). 
No significant differences in the proportions of cytNK, regNK, 
and CD3+CD56+CD8+ cells’ subsets were observed between MSP 
and NPMS and between MSP and HP.
Regarding sex hormone levels, we did not observe differences 
during pregnancy between MSP and HP. However, a significant 
decreased estrogen levels in MSP with respect to HP was shown 
during the PP (p = 0.04). No correlation was showed among NK 
and NKT cell subsets and sex hormones.
gender effects on nK cells
To evaluate gender effects, we analyzed global differences 
between non-pregnant women and men in both MS and healthy 
groups. Although estrogen levels have a significantly differ-
ent distribution in women and men (healthy: p <  0.001; MS: 
p = 0.002), no gender differences were observed in the propor-
tions of any NK and NKT populations studied in neither healthy 
nor MS patients.
There were, however, differences when comparing subsets 
between MS and the healthy group when considered by 
represents less than 1% of total CD3+CD56+CD8+ cells (data not 
shown), non-significant differences were observed in γδ-T cells 
among all groups studied. Differences in CD3+CD56+CD8+ cells 
would be ascribed to the CD8+NKT-like population. To avoid 
controversy and enhance accuracy of the nomenclature, we will 
use the term CD3+CD56+CD8+ herein for this subset instead of 
“CD8+ NKT-like cells.” The CD3+CD56+CD4+ T subpopulation 
was not considered for the analysis due to its very low percentage 
of the population studied. All NK and CD3+CD56+CD8+ subsets 
are given as percentage of total lymphocytes.
Progesterone and estrogen hormonal 
Quantification
Blood samples were obtained around 8:30 a.m. Serum was 
separated in a refrigerated centrifuge and stored at −80°C until 
use. Serum progesterone and estrogen levels were determined 
in the luteal and follicular phases of the menstrual cycle of both 
healthy and MS women and men groups by a chemiluminescence 
assay (Immuno I, Bayer, Germany) following the manufacturer’s 
instructions.
statistical analysis
Descriptive data are presented as median (interquartile range). 
When multiple groups with continuous outcomes were com-
pared, the non-parametric Kruskal–Wallis rank sum test was 
used, followed by pairwise Mann–Whitney tests if the former 
indicated significant differences. Correlations were assessed 
using Spearman correlation (rs) coefficients. Data were analyzed 
with SPSS v.19 (Chicago, IL, USA) and GraphPad Prism software 
(CA, USA). A p-value less than 0.05 was considered as statistically 
significant.
resUlTs
nK and cD3+cD56+cD8+ cell subsets’ 
changes within the Menstrual cycle
As previously reported (29), no significant differences neither for 
the values of total NK cells nor for any of the NK cell subsets 
between the days 1–3 and 14 of the menstrual cycle of the control 
group of normal fertile women were found (data not shown). In 
parallel, no statistically significant differences in the percentage 
of CD3+CD56+CD8+ cells during the two phases of menstrual 
cycle were observed. As a conclusion of this part, the study of 
NK and NKT cells could be performed at any time-point of the 
menstrual cycle. As expected, sex hormone levels significantly 
increased on day 14 of the menstrual cycle with respect to day 1–3 
(p < 0.001): estrogens [39.6 (33.2–54.6) vs. 168.9 (100.0–584.7)] 
and progesterone [0.4 (0.3–0.6) vs. 3.3 (1.3–7.3)].
nK and cD3+cD56+cD8+ cell subsets’ 
changes during Pregnancy
Healthy pregnant women (HP) showed an increased propor-
tion of the regulatory CD56bright subpopulation [0.44 (0.3–0.73) 
vs. 0.33 (0.23–0.58); p = 0.015] compared to the non-pregnant 
healthy control women (NPHC) (Figure 2). No differences were 
observed in CD3+CD56+CD8+ in HP and NPHC.
FigUre 3 | (a) Early activation marker CD69 expression by peripheral blood regCD56bright (CD3−CD56+CD16−), cytCD56dim (CD3−CD56+CD16+), and 
CD3+CD56+CD8+ cell subsets throughout pregnant multiple sclerosis (MS) women (MSP; n = 30), non-pregnant MS women (NPMS; n = 30), and healthy pregnant 
women (HP; n = 13). The bar represents the median value, and individual dots indicate single donor values. (B) CD69 expression longitudinally studied during each 
trimester of pregnancy (1T, 2T, 3T) and postpartum phase in pregnant women. Y-axis represents the media values. Mann–Whitney statistical test was used for 
calculation of the reported p-value. Also, p < 0.05 was considered to be statistically significant. Statistical significance is marked as *p < 0.05 and **p < 0.001.
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gender: when comparing with healthy men, MS men showed 
a significantly increased activation of both cytCD56dim NK 
and CD3+CD56+CD8+ cells. The most activated subset was 
cytCD56dim, with a fourfold increase in CD69 expression [11.34 
(5.45–33.94) vs. 2.76 (1.89–7.90), p  =  0.013]. Also, MS men 
had significantly higher activated CD3+CD56+CD8+ cells than 
healthy men [8.39 (5.89–27.02) vs. 3.93 (2.04–6.53), p = 0.017] 
(Figure 4), suggesting its relevance in MS pathophysiology.
For women, MS women disclosed significantly higher 
proportions of the regCD56bright subset compared to healthy 
women [0.54 (0.42–0.78) vs. 0.33 (0.23–0.58), p  =  0.003] 
(Figure 5). There were no significant differences in cytNK and 
CD3+CD56+CD8+ cells’ proportions between both MS and 
healthy groups.
We also evaluated the balance between cytotoxic vs. regula-
tory NK cells through the cytCD56dim/regCD56bright ratio and the 
cytCD56dim/CD3+CD56+CD8+ cells ratio. We found significantly 
increased ratios of CD69 expression in MS women with respect 
to healthy women (cytCD56dim/CD3+CD56+CD8+, p  <  0.001; 
cytCD56dim/regCD56bright, p = 0.06) (Figure 6).
DiscUssiOn
The most remarkable finding was the significant increase in 
activation of blood CD3+CD56+CD8+ cells in MS patients 
during pregnancy with respect to NPMS and even above that 
of the healthy pregnant women. In addition, healthy full-term 
pregnancies showed also significantly higher activation of 
CD3+CD56+CD8+ cells with respect to healthy non-pregnant 
women. The immunology of pregnancy is characterized by an 
anti-inflammatory shift paradigm in peripheral blood based on 
CD4+ Treg and Th differentiation toward Th2 and regulatory 
CD4+ T cells (Treg) (30–32). Changes in hormone levels during 
pregnancy, such as increased estrogens and progesterone, may 
FigUre 5 | Percentage of regcD56bright in women from hc (n = 32) 
and multiple sclerosis (Ms) (n = 30) groups. The bar represents the 
median value, and individual dots indicate single donor values. Mann–
Whitney statistical test was used for calculation of the reported p-value. Also, 
*p = 0.003 was considered to be statistically significant.
FigUre 4 | expression of cD69 (percentage) of natural killer (nK) subsets regcD56bright (cD3−cD56+cD16−), cytcD56dim (cD3−cD56+cD16+), and 
cD3+cD56+cD8+ cells in men (left) [hc: n = 9, multiple sclerosis (Ms): n = 10] and women (right) (hc: n = 32, Ms: n = 30) Ms compared to healthy 
individuals. Mann–Whitney statistical test was used for calculation of the reported p-value. The bar represents the median value, and individual dots indicate single 
donor values. Also, *p < 0.05 was considered to be statistically significant.
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FigUre 6 | ratio of cytcD56dim and regulatory cell subsets 
(regcD56bright or cD3+cD56+cD8+) activity in multiple sclerosis (Ms) 
men (hc: n = 9, Ms: n = 10) and women (hc: n = 32, Ms: n = 30). Data 
are plotted with box and whiskers (10–90% range), and the bar represents 
the median value. Also, p < 0.05 was considered to be statistically 
significant. Statistical significance is marked as **p < 0.001 and #p = 0.06 
(trend).
be responsible for these changes. Thus pregnancy, through the 
promotion of an immunoregulatory status, has been related to 
have the most beneficial effects on the severity of several Th1/
Th17-driven autoimmune diseases (33).
No reliable studies have shown the role of NKT in the setting 
of pregnancy and in MS, although our data suggest a potential 
role of this activated regulatory subset in the pregnancy-related 
remission of disease activity. Here, we observe that the highest 
activation status of CD3+CD56+CD8+ cells occurred at the third 
trimester of gestation, when sex hormones reach their peak, and 
thereby would coincide with the reported strongest decrease in 
relapse rate in MS patients (34). Further, persistent although 
lower activation of CD3+CD56+CD8+ cells was observed at PP, 
when the probability of MS relapse increases. The pattern of 
activation of CD3+CD56+CD8+ cells was quite similar to that 
reported by our group and others for Treg, which have a peak 
during the second and third trimesters and declining at PP (35), 
which could reflect their possible implication in MS activity dur-
ing pregnancy and PP. Regulatory function of CD8+NKT cells 
has been previously reported in several disease mouse models 
characterized by Th1 immune responses through the production 
of a Th2-type cytokine profile (24, 36). The changes observed here, 
especially the high activation status of the regulatory subsets, lead 
us to speculate that CD8+NKT cells could play an important role 
in modulating T cell responses and in ameliorating MS during 
pregnancy.
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Epidemiological and clinical data clearly underline the sexual 
dimorphism in MS incidence and disease course. This fact directs 
to the influence of hormones on immune cells, and estrogens 
are known to exert opposing and dose-dependent effects on the 
immune response. There is controversy about specific effects of 
sex hormones on NK activity (37). In one hand, low estrogen 
levels facilitate a cell-mediated proinflammatory immune 
response, whereas their relatively high levels (pregnancy) 
promote anti-inflammatory Th2 and Treg responses (38). Our 
findings showed no differences between the follicular and 
ovulatory phases in the activity or proportions of the three NK 
and CD3+CD56+CD8+ populations studied in healthy subjects. 
Concerning gender-based differences, our results showed no 
differences in peripheral NK or CD3+CD56+CD8+ cell numbers 
or activity between women and men in healthy and MS groups. 
Moreover, we did not observe correlation among sex hormones 
estradiol and progesterone with NK and CD3+CD56+CD8+ 
cells’ subsets. Reported studies on the fluctuation of NK cells 
subsets during the menstrual cycle are heterogeneous, showing 
no changes during the cycle, increase, or even reduction in the 
luteal phase (37, 39). These results may in part be due to varying 
definitions of the NK populations and methodologies to define 
these cells and to measure activity.
However, differences between MS patients and healthy controls 
differentiated by gender were remarkable. Our findings showed 
increased activation of the cytotoxic CD56dimNK subset in men 
affected of MS with respect to healthy men. These major increase 
of the cytotoxic NK subset studied would be compatible with 
previous results reporting increased circulating cytCD56dim NK 
levels expressing perforin in primary progressive MS patients, a 
clinical form with men’ predominance (40), which might suggest 
a role of this NK cell subset in the pathophysiology and progres-
sion of the disease. The increased activation of the regulatory 
CD3+CD56+CD8+ subset reported in our series of MS men could 
be reflecting a compensatory activation to control the inflamma-
tory activity. On the other hand, MS women show an increased 
proportion of regCD56bright NK cells compared to healthy women. 
Thus, the increased activation of the cytotoxic CD56dim NK subset 
in men, and the increased proportion of regCD56bright NK cells in 
women, would be in line with the sex differences reported in the 
clinical course of MS. Although prevalence in women is higher, 
there is evidence that women generally have an earlier onset of 
disease, slightly lower prevalence of PP-MS, and show in general 
less progression of disability than men (41).
Particular NK cell subtypes may have different roles in 
controlling CNS inflammation in MS patients, and the balance 
between immunity and tolerance would be orchestrating the 
adaptive autoreactive response. MS men showed an increased 
ratio of cytotoxic NK vs. regulatory NK/NKT cells’ activation; 
whereas MS women showed a significantly increased proportion 
regCD56bright NK cells than healthy women. However, the immune 
balance between cytotoxic and regulatory NK cells was highly 
increased in MS patients, more marked in women. In terms of 
NK cells’ functions, we could speculate that more than a defec-
tive regulatory response, an imbalance due to enhanced cytotoxic 
activity could contribute to the MS pathological processes.
Understanding the distribution and function of NK and NKT 
cells’ subsets related to gender disparity and the effects during 
pregnancy status in MS may help to have a global vision and 
to fully understand the implication of innate immunity on MS. 
Differences observed and beneficial effects of pregnancy in MS 
highlight the relevance of NKT cells. Further studies on CD8+ 
NKT cells function and their role in pregnancy beneficial effects 
on MS are warranted to move forward more effective MS treat-
ments. NKT-like cells would be potential therapeutical targets in 
MS as well as therapies that enhance their numbers or activation.
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